05:21 AM EST, 11/26/2024 (MT Newswires) -- (Updates to add EU's comment in the fourth paragraph)

Novo Nordisk's ( NVO ) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent ( CTLT ) , Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.

The report said that Catalent ( CTLT ) is preparing senior management for the deal to go through.

The deal, crucial for boosting production of Novo Nordisk's ( NVO ) blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.

The European Commission declined to comment. Novo Nordisk ( NVO ) and Catalent ( CTLT ) did not immediately respond to requests for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)